OncoMatch/Clinical Trials/NCT06749860
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Is NCT06749860 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Disitamab Vedotin + tislelizumab + bevacizumab for lung cancer.
Treatment: Disitamab Vedotin + tislelizumab + bevacizumab — The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2 mutation/amplification/expression. The main questions it aims to answer are: 1. objective response rate; 2. Progression-Free Survival; 3. Overall Survival; 4. Disease Control Rate; 5. Duration of Response.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: HER2 (ERBB2) amplification
Required: HER2 (ERBB2) expression (ihc 1+, 2+, or 3+) (ihc 1+, 2+, or 3+)
Required: HER2 (ERBB2) mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: HER2 antibody
Prior treatment with HER2 antibodies
Cannot have received: antibody-drug conjugate
Prior treatment with ... antibody-drug conjugates
Lab requirements
Blood counts
ANC >= 1.5×10^9/L; platelets >= 100×10^9/L; hemoglobin >= 90g/L (no transfusion in past 7 days)
Kidney function
serum creatinine <= 1.5x ULN
Liver function
total bilirubin <= 1.5x ULN; AST/ALT <= 2.5x ULN (<= 5x ULN with liver metastasis)
Adequate hematologic function ... Adequate liver function ... Adequate renal function ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06749860 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HER2 antibody, antibody-drug conjugate disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 amplification is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 expression (ihc 1+, 2+, or 3+) is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify